Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3000 participants.
Also called NCT07753200
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,000 participants
- Sponsor
- Registry
-
NCT07753200
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT07753200. Randomized; single masking; primary purpose treatment. Start 2026-07-20 (actual); primary completion 2031-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
- Acronym
- SMARTDECISION3
- Condition
- Atrial Fibrillation (AF)
- Condition
- Coronary Arterial Disease (CAD (coronary artery disease))
- Intervention (Drug)
- Edoxaban
- Intervention (Drug)
- Apixaban
- Lead sponsor
- Samsung Medical Center
Record details
- Record id
cardio:ct-nct07753200- Content hash
cf4228458b32290da1157daeedcc253d86ca64162ddcfd9978a4864dc20977b5